TLR3 and colorectal carcinoma: To explore whether modulation of the TLR3 pathway by the gut virome could impact CRC treatment, we investigated how antiviral-induced virome depletion and TLR3 activation through the agonist Poly(I:C) affect immune cell recruitment and the efficacy of 5-FU chemotherapy.